<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">952</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2024-19-3-199-205</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CURRENT TREATMENT ASPECTS FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND HIV INFECTION</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ АСПЕКТЫ ПОДХОДОВ К ЛЕЧЕНИЮ ОНКОГЕМАТОЛОГИЧЕСКИХ ПАЦИЕНТОВ С ВИЧ-ИНФЕКЦИЕЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Plasmablastic pituitary lymphoma in a patient with human immunodeficiency virus: brief review of the literature and clinical case report</article-title><trans-title-group xml:lang="ru"><trans-title>Плазмобластная лимфома гипофиза у пациента с вирусом иммунодефицита человека: краткий обзор литературы и описание клинического наблюдения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0814-4941</contrib-id><name-alternatives><name xml:lang="en"><surname>Martynov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Мартынов</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Denis V. Martynov </bold></p><p><italic>23 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><bold>Денис Владимирович Мартынов </bold></p><p><italic>115522 Москва, Каширское шоссе, 23</italic></p></bio><email>martynovmed@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1469-2365</contrib-id><name-alternatives><name xml:lang="en"><surname>Valiev</surname><given-names>T. T.</given-names></name><name xml:lang="ru"><surname>Валиев</surname><given-names>Т. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>23 Kashirskoe Shosse, Moscow 115522, </italic></p><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991,</italic></p><p><italic>2/1 Barrikadnaya St., Moscow 125993</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 23,</italic></p><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2,</italic></p><p><italic>125993 Москва, ул. Баррикадная, 2/1</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3576-6156</contrib-id><name-alternatives><name xml:lang="en"><surname>Odzharova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Оджарова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>23 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 23</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8443-8816</contrib-id><name-alternatives><name xml:lang="en"><surname>Ryabukhina</surname><given-names>Yu. E.</given-names></name><name xml:lang="ru"><surname>Рябухина</surname><given-names>Ю. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>143081 Московская обл., д. Лапино, 1‑е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991,</italic></p><p><italic>111 1<sup>st</sup> Uspenskoe Shosse, Lapino, Moscow region 143081</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2,</italic></p><p><italic>143081 Московская обл., д. Лапино, 1‑е Успенское шоссе, 111</italic></p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9502-072X</contrib-id><name-alternatives><name xml:lang="en"><surname>Mikhailova</surname><given-names>S. N.</given-names></name><name xml:lang="ru"><surname>Михайлова</surname><given-names>С. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>23 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 23</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-03" publication-format="electronic"><day>03</day><month>09</month><year>2024</year></pub-date><volume>19</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>199</fpage><lpage>205</lpage><history><date date-type="received" iso-8601-date="2024-09-03"><day>03</day><month>09</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-09-03"><day>03</day><month>09</month><year>2024</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/952">https://oncohematology.abvpress.ru/ongm/article/view/952</self-uri><abstract xml:lang="en"><p>Plasmoblastic lymphoma is a rare, aggressive B-cell malignancy with poor long-term survival. Plasmoblastic lymphoma occurs most commonly in patients infected with human immunodeficiency virus (HIV), but cases associated with solid organ transplantation have also been reported, less commonly plasmoblastic lymphoma registers in immunocompetent patients. The disease is more common in male patients (75 %) aged from 8 to 62 years (median age 50 years), and most often the tumor lesions are localized in the oral cavity. Rare localizations of plasmoblastic lymphoma include pleura, testicles, mammary glands, lungs, and skin. As casuistic areas of lesions, the central nervous system can be noted.</p><p>The article describes a clinical case of HIV-positive pediatric patient with rare plasmoblastic lymphoma of chiasmosellar zone. The disease was complicated with secondary hypocorticism and hypotyreosis, a deficiency of somatotrophic hormone and diabetes insipidus.</p></abstract><trans-abstract xml:lang="ru"><p>Плазмобластная лимфома – редкое, агрессивное В-клеточное злокачественное новообразование с низкими показателями отдаленной выживаемости. Чаще всего встречается у пациентов, инфицированных вирусом иммунодефицита человека (ВИЧ), но также регистрируются случаи, связанные с трансплантацией солидных органов, реже – у иммунокомпетентных пациентов. Заболевание чаще встречается у пациентов мужского пола (75 %) в возрасте от 8 до 62 лет (медиана возраста 50 лет). Очаг опухолевого поражения обычно локализуется в полости рта. К редким локализациям плазмобластной лимфомы относятся плевра, яички, молочные железы, легкие, кожа. В качестве казуистических зон поражения можно отметить центральную нервную систему.</p><p>В статье описан клинический случай плазмобластной лимфомы у ребенка с ВИЧ-инфекцией с редкой локализацией в хиазмально-селлярной области. Течение заболевания осложнилось вторичным гипокортицизмом и гипотиреозом, дефицитом соматотропного гормона и несахарным диабетом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>plasmoblastic lymphoma</kwd><kwd>human immunodeficiency virus</kwd><kwd>diagnosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>плазмобластная лимфома</kwd><kwd>вирус иммунодефицита человека</kwd><kwd>диагностика</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Delecluse H.J., Anagnostopoulos I., Dallenbach F. et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89(4):1413–20.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Morscio J., Dierickx D., Nijs J. et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014;38(7):875–86. DOI: 10.1097/PAS.0000000000000234</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lopez A., Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer 2018;8:63–70. DOI: 10.2147/BLCTT.S142814</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Montes-Moreno S., Gonzalez-Medina A.R., Rodriguez-Pinilla S.M. et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95(8):1342–9. DOI: 10.3324/haematol.2009.016113</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Firsova M.V., Solov’ev M.V., Kovrigina A.M. et al. Plasmablastic lymphoma with primary impairment of bone marrow in a HIVnegative patient: a literature review and a case report. Klinicheskaya onkogematologiya = Clinical Oncohematology 2022;15(4):356–64. (In Russ.). DOI: 10.21320/2500-2139-2022-15-4-356-364</mixed-citation><mixed-citation xml:lang="ru">Фирсова М.В., Соловьев М.В., Ковригина А.М. и др. Плазмобластная лимфома с первичным поражением костного мозга у пациента с ВИЧ-отрицательным статусом: обзор литературы и собственное клиническое наблюдение. Клиническая онкогематология 2022;15(4):356–64. DOI: 10.21320/2500-2139-2022-15-4-356-364</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Dong H.Y., Scadden D.T., de Leval L. et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein–Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 2005;29(12):1633–41. DOI: 10.1097/01.pas.0000173023.02724.1f</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Song M.K., Chung J.S., Shin H.J. et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012;91(5):697–703. DOI: 10.1007/s00277-011-1357-2</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Teruya-Feldstein J., Chiao E., Filippa D.A. et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004;15(11):1673–9. DOI: 10.1093/annonc/mdh399</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Loghavi S., Alayed K., Aladily T.N. et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 2015;8:65. DOI: 10.1186/s13045-015-0163-z</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Castillo J.J., Bibas M., Miranda R.N. The biology and treatment of plasmablastic lymphoma. Blood 2015;125(15):2323–30. DOI: 10.1182/blood-2014-10-567479</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Tchernonog E., Faurie P., Coppo P. et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol 2017;28(4):843–8. DOI: 10.1093/annonc/mdw684</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Qunaj L., Castillo J.J., Olszewski A.J. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma 2018;59(6):1375–83. DOI: 10.1080/10428194.2017.1387912</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Castillo J.J., Furman M., Beltrán B.E. et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012;118(21):5270–7. DOI: 10.1002/cncr.27551</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chapman J., Gentles A.J., Sujoy V. et al. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia 2015;29(11):2270–3. DOI: 10.1038/leu.2015.109</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Valera A., Balagué O., Colomo L. et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34(11):1686–94. DOI: 10.1097/PAS.0b013e3181f3e29f</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bogusz A.M., Seegmiller A.C., Garcia R. et al. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol 2009;132(4):597–605. DOI: 10.1309/AJCPFUR1BK0UODTS</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Valera A., Colomo L., Martínez A. et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol 2013;26(10):1329–37. DOI: 10.1038/modpathol.2013.73</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Montes-Moreno S., Martinez-Magunacelaya N., ZecchiniBarrese T. et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol 2017;30(1):85–94. DOI: 10.1038/modpathol.2016.162</mixed-citation><mixed-citation xml:lang="ru">Montes-Moreno S., Martinez-Magunacelaya N., Zecchini-Barrese T. et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol 2017;30(1):85–94. DOI: 10.1038/modpathol.2016.162</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><mixed-citation>Xia Y., Xu-Monette Z.Y., Tzankov A. et al. Loss of PRDM1/ BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia 2017;31(3):625–36. DOI: 10.1038/leu.2016.243</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Colomo L., Loong F., Rives S. et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28(6):736–47. DOI: 10.1097/01.pas.0000126781.87158.e3</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Harmon C.M., Smith L.B. Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 2016;140(10):1074–8. DOI: 10.5858/arpa.2016-0232-RA</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Marini C., Baldaia H., Trigo F. et al. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol 2016;91(8):E324. DOI: 10.1002/ajh.24375</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Castillo J.J., Winer E.S., Stachurski D. et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010;51(11): 2047–53. DOI: 10.3109/10428194.2010.516040</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Baryakh E.A., Kremenetskaya A.M., Kravchenko S.K. et al. New short high-intensity treatment protocol for adult Burkitt-like lymphoma BPL-M-04: interim results. Gematologiya i transfuziologiya = Hematology and Transfusiology 2006;51(6):3–11. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Барях Е.А., Кременецкая А.М., Кравченко С.К. и др. Новый короткий высокоинтенсивный протокол терапии Беркиттоподобной лимфомы взрослых БПЛ-М-04: промежуточные результаты. Гематология и трансфузиология 2006;51(6):3–11.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><mixed-citation>Castillo J.J., Guerrero-Garcia T., Baldini F. et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol 2019;184(4):679–82. DOI: 10.1111/bjh.15156</mixed-citation></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Schommers P., Wyen C., Hentrich M. et al. Poor outcome of HIVinfected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 2013;27(5):842–5. DOI: 10.1097/QAD.0b013e32835e069d</mixed-citation><mixed-citation xml:lang="ru">Schommers P., Wyen C., Hentrich M. et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 2013;27(5):842–5. DOI: 10.1097/QAD.0b013e32835e069d</mixed-citation></citation-alternatives></ref></ref-list></back></article>
